Status:

COMPLETED

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

Lead Sponsor:

Dizal Pharmaceuticals

Conditions:

Nonsmall Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This study will treat patients with advanced NSCLC who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand wha...

Detailed Description

A phase I/II, open-label, multicentre study to investigate the safety, tolerability, pharmacokinetics and anti-tumour activity of AZD4205 as monotherapy or in combination with Osimertinib in patients ...

Eligibility Criteria

Inclusion

  • Obtained written informed consent
  • Patients must have histological or cytological confirmation of activating EGFR mutation positive NSCLC and have failed prior EGFR TKIs treatment.
  • Patients must exhibit Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Adequate bone marrow reserve and organ system functions

Exclusion

  • Any unsolved toxicity \> CTCAE grade 1 from previous anti-cancer therapy (except alopecia)
  • Active viral or bacterial infections;
  • Active or latent tuberculosis;
  • History of interstitial lung disease (ILD)
  • History of heart failure or QT interval prolongation
  • Immunodeficiency diseases;
  • Active CNS metastases
  • Treatment with an EGFR TKI (e.g., erlotinib or gefitinib) within 8 days or approximately 5 x half-life, whichever is longer, of the first dose of study treatment

Key Trial Info

Start Date :

April 16 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 10 2020

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT03450330

Start Date

April 16 2018

End Date

January 10 2020

Last Update

August 24 2020

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

St George Hospital

Sydney, New South Wales, Australia

2

Austin Hospital

Heidelberg, Victoria, Australia, 3084

3

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

4

Northern Cancer Institute St Leonards

Sydney, Australia, 2066